Skip to content

Spanish Registry of Systemic Treatments in Psoriasis (Biobadaderm)

(1)Miembros del grupo BIOBADADERM, Grupo de psoriasis de la AEDV. The Working Group on Psoriasis of the Spanish Academy of Dermatology and Venereology has initiated BIOBADADERM, a registry of patients with psoriasis receiving treatment with biologic drugs, in order to assess the long-term risk of adverse events (AEs). A multicenter study was undertaken in 2 cohorts of patients with psoriasis: patients receiving biologic therapy and patients receiving nonbiologic systemic therapy other than phototherapy. Similar numbers of patients were included in each group. The purpose of Biobadaderm is a to study the safety of systemic therapy in psoriasis. To compare the safety of biologics and classic systemic treatment.

Spanish Registry of Systemic Treatments in Psoriasis (Biobadaderm) 2PDF Source for ‘Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice..’. The Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology (BIOBADADERM) includes patients with psoriasis who are receiving systemic therapy, including biologics. The goal of BIOBADADERM is to document safety outcomes. Methods: Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were grouped in elderly ( 65 years old) and younger patients.

Background: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice. Methods: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. Systemic psoriasis therapy shows high between-countries variation. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report: Actas dermo-sifiliograficas 2011. The Working Group on Psoriasis of the Spanish Academy of Dermatology and Venereology has initiated BIOBADADERM, a registry of patients with psoriasis receiving treatment with biologic drugs, in order to assess the long-term risk of adverse events (AEs). BIOBADADERM, a registry of patients with psoriasis receiving treatment with biologic drugs, in order to assess the long-term risk of adverse events (AEs). A multicenter study was undertaken in 2 cohorts of patients with psoriasis: patients receiving biologic therapy and patients receiving nonbiologic systemic therapy other than phototherapy.

Pubpdf

Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain. Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. Title: Census of Centers That Perform Mohs’ Micrographic Surgery in Spain and Description of Their Activity: A Feasibility Study for the Mohs’ Micrographic Surgery Registry of the Foundation of the Spanish Academy of Dermatology and VenereologyAuthor(s): Alonso-Alonso, T. Title: Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? Title: Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registryAuthor(s): Carretero, G. Psoriasis as a Systemic Inflammatory disease: Genetic and immunologic background. W 3 – Treatments in Psoriatic Arthritis in adults and children.

Risk Of Adverse Events In Psoriasis Patients Receiving Classic Systemic Drugs And Biologics In A 5-year Observational Study Of Clinical Practice: 2008-2013 Results Of The Biobadaderm Registry Universitat De Barcelona Campus Of